Grail Shares Halve as UK Trial Misses Primary Endpoint, Clouding FDA Path
GRAIL Inc. shares plummeted almost 50% in Friday trading following disappointing results from a major UK study of its multi-cancer early detection test. The trial's failure to hit its primary endpoint complicates the company's regulatory and reimbursement strategy.
Technology
